Spoken Alpha
PetVivo Holdings, Inc.
PetVivo Holdings manufactures and commercializes veterinary medical devices made from protein-based biomaterials that mimic natural tissue. The company's lead product, Spryng®, is an intra-articular injection for treating osteoarthritis and joint lameness in dogs and horses.
PetVivo Holdings, Inc is a Healthcare company operating in Medical Devices with a $25.8M market cap.
Most recent reported earnings: Q3 FY2027 (Dec 30, 2026).
14 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for PETV.
$ curl https://api.spokenalpha.com/v1/companies/PETVFAQ
Spoken Alpha indexes PETV's earnings call transcripts at https://spokenalpha.com/companies/PETV. Each call links to attributed speakers and parsed analyst Q&A. PetVivo Holdings, Inc.'s own investor relations page is at https://www.petvivo.com/investors.
PetVivo Holdings, Inc. (PETV) held its most recent earnings call on 2025-11-14, covering fiscal Q2 2026.
PetVivo Holdings, Inc. (PETV) operates in the Healthcare sector (Medical Devices industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2027 | 2026-12-30 | $-0.11 | — | — | — | — | — | Finnhub |
| Q2 FY2027 | 2026-09-29 | $-0.07 | — | — | — | — | — | Finnhub |
| Q1 FY2027 | 2026-08-12 | $-0.09 | — | — | $337.6K | — | — | EODHDDisagrees |
| Q4 FY2026 | 2026-06-28 | — | — | — | $254.7K | — | — | EODHD |
| Q3 FY2026 | 2026-02-17 | $-0.07 | — | — | $286.1K | — | — | EODHD |
| Q2 FY2026 | 2025-11-12 | $-0.11 | — | — | $303.3K | — | — | EODHD |
| Q1 FY2026 | 2025-08-11 | $-0.11 | — | — | $297.5K | — | — | EODHD |
| Q4 FY2025 | 2026-02-17 | $-0.07 | — | — | $286.1K | — | — | EODHD |
| Q3 FY2025 | 2025-02-13 | $-0.09 | $0.00 | — | $583.3K | — | — | EODHD |
| Q2 FY2025 | 2024-11-14 | $-0.11 | — | — | $200.7K | — | — | EODHD |
| Q1 FY2025 | 2024-08-13 | $-0.16 | — | — | $123.8K | — | — | EODHD |
| Q4 FY2024 | 2024-06-27 | $-0.14 | $-0.32 | +56.3% | $48.3K | — | — | EODHD |
| Q3 FY2024 | 2024-02-11 | $-0.12 | — | — | $595.9K | — | — | EODHD |
| Q2 FY2024 | 2023-11-13 | $-0.28 | — | — | $207.4K | — | — | EODHD |
| Q1 FY2024 | 2023-08-09 | $-0.25 | — | — | $117.2K | — | — | EODHD |
| Q4 FY2023 | 2023-06-28 | $-0.21 | $-0.21 | 0.0% | $125.6K | — | — | EODHD |
| Q3 FY2023 | 2023-02-08 | $-0.23 | $-0.23 | 0.0% | $510.1K | — | — | EODHD |
| Q2 FY2023 | 2022-11-09 | $-0.21 | $-0.25 | +16.0% | $223.3K | — | — | EODHD |
| Q1 FY2023 | 2022-08-10 | $-0.20 | $-0.23 | +13.0% | $58.2K | — | — | EODHD |
| Q4 FY2022 | 2022-06-23 | $-0.19 | $-0.19 | 0.0% | $55.5K | — | — | EODHD |
Source: EODHD, Finnhub. Some rows have cross-provider disagreement flags (see badge). PETV reported actuals as published; sparse fields render as —.